Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Eur Urol Oncol. 2018 Jun 6;1(4):325–337. doi: 10.1016/j.euo.2018.04.019

Figure 3. AR signaling can be perturbed both genetically and pharmacologically in the PDE model.

Figure 3

A. Knockdown of AR was achieved through lentirviral transduction of PDE with an AR directed shRNA for 6 days. Representative images show AR and Ki67 IHC for shCon and shAR after 6 days. Right: Expression of AR and AR target genes (PSA, FKBP5, and TMPRSS2) mRNA expression from tumor samples treated with shCon and shAR for 2, 4, and 6 days, n=3. B. Representative images (10X and 40X magnification) are shown for vehicle, AR antagonist (1 μM Enzalutamide), and AR antagonist (1 μM Bicalutamide) treated tumors after 6 days of treatment, n=3. C. Expression of AR target genes (PSA, TMPRSS2, and FKBP5) mRNA expression from vehicle, 1 μM Enzalutamide, and 1 μM Bicalutamide treated PDE. Average fold change of three PDE shown. n=3, *p< 0.05. D. Waterfall plot depicting the percentage change of PSA in the culture medium with 1 μM Enzalutamide treatment. Blue bars represent patients with ≥ 25% decrease in PSA, black bars represent no change in PSA, and red bars represent ≥ 25% increase in PSA.